Two retrospective studies indicated that bisphosphonates combined with sunitinib/sorafenib could improve the response rate, PFS and OS in renal cell carcinoma with bone metastases [16, 17], which suggested that the combination of bisphosphonates and EGFR-TKIs probably also bring benefits to NSCLC. This evidence concerns the gene EGFR and renal cell carcinoma.